MEPs fight AMR
MEP Interest Group on Antimicrobial Resistance
deaths AMR is annually responsible for in Europe
billion € yearly healthcare costs and productivity losses due to AMR in Europe
million deaths per year worldwide by 2050 if no action on AMR is taken
million people who could be pushed into extreme poverty by 2030 by AMR.
MEPs FIGHT AMR
2019-2024 strategic work programme of the
MEP Interest Group on Antimicrobial Resistance
The European Parliament can play a key role in boosting actions to tackle AMR at EU level.
The MEP Interest Group on AMR offers a unique opportunity to address AMR, which not only directly affects the lives of all Europeans but also threatens global economic development.
Latest Developments
The Pharmaceutical Strategy is a chance to tackle antimicrobial resistance that Europe cannot miss says the MEP Interest Group on AMR
Members of the European Parliament from the MEP Interest Group on AMR and supporting MEPs call on the European Commission to ensure the proposed Pharmaceutical Strategy includes strong measures to tackle antimicrobial resistance
It’s all about people – a powerful launch of the new MEP Interest Group on AMR
A packed room of key actors, including Health Commissioner Stella Kyriakides, committed to tackling Antimicrobial Resistance (AMR) from a One Health approach, joined MEPs for the launch of the MEP interest group on AMR which took place on 19 February 2020 in the...
MEPs join forces to boost European Parliament actions to tackle antimicrobial resistance (AMR)
New MEP Interest Group on AMR launched on 19 February 2020 will push for more European cooperation to stop antimicrobial resistance.
BECOME AN AMR CHAMPION
What is the MEP Interest Group on AMR?
- Ensuring that AMR is high on the EU policy agenda and that the European Parliament plays a key role in boosting AMR action
- Stressing the need for urgent action through a multi-sectoral One Health approach, which addresses human, animal and environmental health
- Ensuring that the EU and its Member States deliver on their commitments and implement effective actions at EU, national and regional level.
Why become a member?
Knowledge –
- Benefit from evidence-based information to build your knowledge to implement effective actions on AMR
- Receive regular updates on policy and scientific developments
Support –
- Receive continuous support from AMR Stakeholder Network members to undertake actions in the European Parliament, including drafting motions for plenary debates, reports, opinions, and/or questions for written answers on AMR across its human, animal and environmental dimensions
- Join other concerned MEPs to keep pressure on the European Commission and Member States to deliver on their commitments
- Receive support to highlight issues of national relevance which have a direct impact on your constituents
Stay Connected –
- be connected to a wide network of civil society organisations across Europe
- engage with other MEPs and decision-makers committed to tackling AMR,
- show your commitment and visibility to tackling this urgent public health threat
What are the aims and objectives for the 2019-2024 term?
- Raise awareness on AMR
- Support the use of target-setting and evaluation in AMR policy-making
- Promote funding for AMR-related investments
- Enable an inclusive EU AMR One Health Dialogue
- Ensure that prevention is at the heart of all AMR action
- Address the market failures in antibiotic research & innovation
- Fight pharmaceutical pollution
- Ensure effective implementation of the EU veterinary medicinal products and medicated feed regulations
Meet the AMR champions
Sarah Wiener, MEP
Greens/EFA, Austria
Chair
Tiemo Wölken, MEP
S&D, Germany
Vice-Chair
Nicolae Ştefănuţă, MEP
RE, Romania
Vice-Chair
Brando Benifei, MEP
S&D, Italy
Fredrick Federley, MEP
RE, Sweden
Piernicola Pedicini MEP
NI, Italy
Tomislav Sokol, MEP
EPP, Croatia
Biljana Borzan, MEP
S&D, Croatia
Frances Fitzgerald, MEP
EPP, Ireland
Sirpa Pietikäinen, MEP
EPP, Finland
István Ujhelyi, MEP
S&D, Hungary
Sara Cerdas, MEP
S&D, Portugal
Roberta Metsola, MEP
EPP, Malta
Jessica Polfjärd, MEP
EPP, Sweden
Olivier Chastel, MEP
RE, Belgium
Juozas OLEKAS, MEP
S&D, Lithuania
Christel Schaldemose, MEP
S&D, Denmark
Sarah Wiener, MEP
Greens/EFA, Austria
Chair
Tiemo Wölken, MEP
S&D, Germany
Vice-Chair
Nicolae Ştefănuţă, MEP
Renew Europe, Romania
Vice-Chair
Brando Benifei, MEP
S&;D, Italy
Biljana Borzan, MEP
S&D, Croatia
Sara Cerdas, MEP
S&D, Portugal
Olivier Chastel, MEP
Renew Europe, Belgium
Fredrick Federley, MEP
Renew Europe, Sweden
Frances Fitzgerald, MEP
EPP, Ireland
Mairead McGuinness, MEP
EPP, Ireland
Roberta Metsola, MEP
EPP, Malta
Piernicola Pedicini, MEP
NI, Italy
Sirpa Pietikäinen, MEP
EPP, Finland
Jessica Polfjärd, MEP
EPP, Sweden
Christel Schaldemose, MEP
S&D, Denmark
Tomislav Sokol, MEP
EPP, Croatia
István Ujhelyi , MEP
S&D, Hungary
How do we work?
The MEP Interest Group was established in November 2019 during World Antibiotic Awareness Week. Further to the first introductory technical internal meeting of the group which took place on 20 January 2020, the Group was officially launched on 19 February 2020 at the European Parliament.
The high-level launch event entitled ‘AMR: Setting the agenda for change’, brought together key players working on AMR, including the European Commissioner for Health and Food Safety and other European Commission representatives, the UN Tripartite organisations collaborating on AMR (FAO/OIE/WHO), Member States’ representatives, members of the AMR Stakeholder Network and other stakeholders. Musician and patient Silviu Ciocanelli, also shared a captivating account of the reality of living with AMR, calling for urgent measures to be taken to protect Europeans.
The MEP Interest Group meets on average twice per year with external stakeholders (annual meeting + side meeting dedicated to a specific AMR-related dimension). Meetings can take the form of debates, workshops, or webinars to discuss, monitor progress and advocate for future actions.
MEPs are free to decide on their level of involvement in meetings and other activities, depending on their interests and agendas. Nonetheless, MEPs are highly encouraged to take part in at least one activity a year.
The Secretariat
The Secretariat of the Interest Group is co-hosted by the European Public Health Alliance (EPHA) and Health Care Without Harm (HCWH) Europe with the support of the AMR Stakeholder Network.
EPHA is a leading Brussels-based NGO advocating for better health in Europe. It is a member-led organisation made up of public health NGOs, patient groups, health professionals and disease groups, working to improve health and strengthen the voice of public health in Europe.
HCWH Europe is the European arm of a global not-for-profit NGO whose mission is to transform healthcare worldwide so that it reduces its environmental footprint, becomes a community anchor for sustainability, and a leader in the global movement for environmental health and justice.
The AMR Stakeholder Network, operating within the framework of the European Commission’s Health Policy Platform, brings together 80 members representing health and environmental NGOs, patient organisations, public health institutes, national and regional authorities and agencies, committed academics and healthcare professionals working on AMR, and other stakeholders, working on AMR.
The MEP Interest Group activities and organisation of meetings at the European Parliament will receive financial support from European Commission Operating Grants of the EU Health Programme & LIFE Programme.
Events
AMR: setting the agenda for change
19 February 2020
Official launch of the MEP Interest Group on AMR – European Parliament.
ABOUT THE AMR STAKEHOLDER NETWORK
Questions?
Zoltán Massay-Kosubek
Policy Manager for Clean Air and Sustainable Mobility
European Public Health Alliance
zoltan@epha.org
+32 2 233 3872
Jean-Yves Stenuick
Pharmaceuticals Policy & Projects Officer
Health Care Without Harm (HCWH) Europe
jean-yves.stenuick@hcwh.org
+32 2503 3137
HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE programme. HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC.